Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel

2024-515674-27-00 Protocol IOA-289-102 Human pharmacology (Phase I) - Other Ended

Start 1 Oct 2024 · End 22 Jul 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol IOA-289-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 2

metastatic pancreatic cancer

Key facts

Sponsor
iOnctura SA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Oct 2024 → 22 Jul 2025
Decision date (initial)
2024-09-17
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-515674-27-00
EudraCT number
2022-000414-33
ClinicalTrials.gov
NCT05586516

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

metastatic pancreatic cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

iOnctura SA

Sponsor organisation
iOnctura SA
Address
Campus Biotech Innovation Park, Avenue De Secheron 15/f2 Avenue De Secheron 15/f2
City
Geneva
Postcode
1202
Country
Switzerland

Scientific contact point

Organisation
iOnctura SA
Contact name
Michael Lahn

Public contact point

Organisation
iOnctura SA
Contact name
Lars van den Veen

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 16 2
Rest of world
United Kingdom
8

Investigational sites

Italy

2 sites · Ended
Azienda Ospedaliera Universitaria Integrata Verona
Centro Ricerche Cliniche di Verona, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Azienda Ospedaliera Universitaria Senese
U.O.C. Immunoterapia Oncologica, Viale Mario Bracci 1, 53100, Siena

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2024-10-01 2024-10-01 2025-01-08

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-30 Italy Acceptable
2024-09-12
2024-09-17
2 SUBSTANTIAL MODIFICATION SM-1 2025-01-22 Italy Acceptable
2025-02-24
2025-02-25
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-04-04 Italy Acceptable
2025-02-24
2025-04-04
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-07-01 Italy Acceptable
2025-02-24
2025-07-01